title: Profile of eliglustat tartrate in the management of Gaucher disease.
abstract: Gaucher disease (GD) is a lysosomal storage disorder caused by the deficient activity of acid beta glucosidase, with consequent accumulation of glucosylceramide in the spleen, liver, bone marrow, and various organs and tissues. Currently, the gold standard for GD treatment is enzyme replacement therapy (ERT). The efficacy of ERT in improving or stabilizing the visceral and hematological symptoms of GD is well-proven. However, since ERT has to be administered by frequent intravenous infusions, this therapeutic approach has an important impact on the patient's quality of life. Eliglustat tartrate is a new substrate reduction therapy for GD, which acts as a specific and potent inhibitor of glucosylceramide synthase and can be administered orally. This review summarizes the results of the preclinical and clinical trials, which experimented with eliglustat, and discusses its possible role in the management of GD, when compared to the currently available treatments and the new experimental approaches.
authors.affiliation: Regional Coordinator Center for Rare Diseases, Academic Hospital of Udine, Udine, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Sechi
authors.affiliation: Regional Coordinator Center for Rare Diseases, Academic Hospital of Udine, Udine, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Dardis
authors.affiliation: Regional Coordinator Center for Rare Diseases, Academic Hospital of Udine, Udine, Italy.
authors.forename: Bruno
authors.initials: B
authors.lastname: Bembi
keywords: Gaucher disease; eliglustat tartrate; enzyme replacement therapy; substrate reduction therapy
references.citation: Eur J Intern Med. 2006 Nov;17 Suppl:S2-5
references.pmid: 17011471
references.citation: Blood. 2005 Jun 15;105(12):4569-72
references.pmid: 15718419
references.citation: Am J Hematol. 2015 Jul;90(7):577-83
references.pmid: 25903392
references.citation: Blood Cells Mol Dis. 2014 Dec;53(4):253-60
references.pmid: 24950666
references.citation: Lancet. 2000 Apr 29;355(9214):1481-5
references.pmid: 10801168
references.citation: JAMA. 2015 Feb 17;313(7):695-706
references.pmid: 25688781
references.citation: J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):442-7
references.pmid: 16763916
references.citation: Br J Haematol. 1993 Oct;85(2):401-5
references.pmid: 8280613
references.citation: J Clin Invest. 1994 Mar;93(3):1288-92
references.pmid: 8132768
references.citation: Blood. 2010 Aug 12;116(6):893-9
references.pmid: 20439622
references.citation: Mol Genet Metab. 2014 Nov;113(3):213-8
references.pmid: 25127542
references.citation: J Inherit Metab Dis. 2010 Aug;33(4):331-8
references.pmid: 20532983
references.citation: N Engl J Med. 1991 May 23;324(21):1464-70
references.pmid: 2023606
references.citation: Am J Hematol. 2008 Dec;83(12 ):937
references.pmid: 18803277
references.citation: J Lipid Res. 2012 Feb;53(2):282-91
references.pmid: 22058426
references.citation: Neurology. 1993 Oct;43(10):1993-7
references.pmid: 8413956
references.citation: J Clin Pharmacol. 2011 May;51(5):695-705
references.pmid: 20864621
references.citation: Skeletal Radiol. 2014 Oct;43(10 ):1353-60
references.pmid: 24816856
references.citation: Mol Genet Metab. 2007 Jul;91(3):259-67
references.pmid: 17509920
references.citation: J Bone Miner Res. 2007 Jan;22(1):119-26
references.pmid: 17032149
references.citation: Ann Neurol. 2008 Nov;64(5):514-22
references.pmid: 19067373
references.citation: Lancet. 2015 Jun 13;385(9985):2355-62
references.pmid: 25819691
references.citation: J Biol Chem. 1999 May 21;274(21):14662-9
references.pmid: 10329660
references.citation: Ann Intern Med. 1995 Jan 1;122(1):33-9
references.pmid: 7985893
references.citation: Br J Haematol. 2014 May;165(4):427-40
references.pmid: 24588457
references.citation: Blood Cells Mol Dis. 2013 Aug;51(2):116-24
references.pmid: 23683771
references.citation: J Pediatr. 2003 Aug;143(2):273-6
references.pmid: 12970647
references.citation: Lancet. 1994 Dec 17;344(8938):1679-82
references.pmid: 7996964
references.citation: Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):249-59
references.pmid: 25987177
references.citation: Semin Hematol. 2004 Oct;41(4 Suppl 5):4-14
references.pmid: 15468045
references.citation: Blood Cells Mol Dis. 2014 Dec;53(4):274-6
references.pmid: 24835462
references.citation: Baillieres Clin Haematol. 1997 Dec;10(4):635-56
references.pmid: 9497856
references.citation: Mol Ther. 2015 May;23(5):835-44
references.pmid: 25655314
references.citation: J Inherit Metab Dis. 2013 May;36(3):543-53
references.pmid: 22976765
references.citation: Eur Cytokine Netw. 1999 Jun;10(2):205-10
references.pmid: 10400826
references.citation: Acta Paediatr. 2008 Apr;97(457):88-93
references.pmid: 18339196
references.citation: Am J Hum Genet. 1989 Mar;44(3):365-77
references.pmid: 2464926
references.citation: J Pathol. 2015 Jan;235(1):113-24
references.pmid: 25256118
references.citation: J Inherit Metab Dis. 2003;26(6):513-26
references.pmid: 14605497